← Back to headlines
EMA Approves New Transport Conditions for Novo Nordisk's GLP-1 Therapy
The European Medicines Agency (EMA) has approved updated transport conditions for Novo Nordisk's injectable GLP-1 therapy used for weight management.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
